Kourosh Rezania

Introduction/Aims Transthyretin amyloidosis (ATTR) proteins can infiltrate skeletal muscle and infrequently cause a myopathy. 99m Technetium‐pyrophosphate ( 99m Tc‐PYP) is a validated biomarker for cardiac involvement in variant and wild‐type ATTR (ATTRv and ATTRwt, respectively). The aim of this study was to test the hypothesis that 99m Tc‐PYP is a biomarker for muscle burden of ATTR. Methods Radioisotope uptake in the deltoid muscles of patients with ATTR was compared to uptake in control subjects without amyloidosis in a retrospective study. 99m Tc‐PYP scans were evaluated in 11 patients with ATTR (7 ATTRv, 4 ATTRwt) and 14 control subjects. Mean count (MC) values were measured in circular regions of interest (ROIs) 2.5–3.8 cm 2 in area. Tracer uptake was quantified in the heart, contralateral chest (CC), and deltoid muscles. Results Tracer uptake was significantly higher over the deltoids and heart but not the CC, in patients with ATTR than in control subjects. MC values were 120.1 ± 43.7 (mean ± SD) in ATTR patients and 78.9 ± 20.4 in control subjects over the heart ( p = 0.005), 73.3± 21.0 and 63.5 ± 14.4 over CC ( p = 0.09), and 37.0 ± 11.7 and 26.0 ± 7.1 averaged over both deltoid muscles ( p = 0.014). Discussion 99m Tc‐PYP is a potential biomarker for ATTR amyloid burden in skeletal muscle.